
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros Corp has reported promising results from its Expanded Access Program (EAP) for narsoplimab, highlighting a significant survival benefit in patients suffering from hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), with a demonstrated two- to three-fold reduction in mortality risk compared to control groups. The absence of approved alternatives in this niche market positions narsoplimab to potentially establish a strong market presence, bolstered by its statistically significant superiority in overall survival rates. Despite some skepticism regarding regulatory outcomes, the compelling clinical data and strategic market positioning support a positive outlook for Omeros's stock as the company advances toward potential product approval.
Bears say
Omeros Corporation is facing significant operational challenges, having accumulated substantial losses with no anticipated profitability for several years, necessitating further capital to fund research and development initiatives. Concerns regarding the uncertain path to FDA approval for its drug candidate narsoplimab, coupled with limited clinical data from a small trial and a prolonged period since the complete response letter without new data, contribute to skepticism about the company's future. Additionally, the indication of a "going concern" in its 3Q24 financial report heightens apprehensions regarding the viability of Omeros's business model and prospects.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares